NxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares
NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $24.48, for a total value of $85,680.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
NxStage Medical, Inc. (NXTM) opened at $23.49 on Friday. NxStage Medical, Inc. has a 52-week low of $20.45 and a 52-week high of $30.80. The firm has a market capitalization of $1,600.32, a PE ratio of -335.57 and a beta of -0.08.
A number of equities analysts have weighed in on the company. Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Northland Securities reissued a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research report on Wednesday, November 8th. ValuEngine lowered NxStage Medical from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, BidaskClub raised NxStage Medical from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $30.25.
ILLEGAL ACTIVITY NOTICE: “NxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2018/02/24/nxstage-medical-inc-nxtm-svp-winifred-l-swan-sells-3500-shares-2.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.